CIBC Private Wealth Group LLC Has $117.23 Million Holdings in Johnson & Johnson (NYSE:JNJ)

CIBC Private Wealth Group LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 823,980 shares of the company’s stock after selling 17,102 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $117,228,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Life Planning Partners Inc acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $21,441,000. RWA Wealth Partners LLC boosted its position in Johnson & Johnson by 18.0% during the fourth quarter. RWA Wealth Partners LLC now owns 365,556 shares of the company’s stock worth $52,867,000 after purchasing an additional 55,700 shares during the period. Schroder Investment Management Group increased its holdings in shares of Johnson & Johnson by 18.1% in the fourth quarter. Schroder Investment Management Group now owns 1,847,350 shares of the company’s stock valued at $267,164,000 after purchasing an additional 282,807 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Johnson & Johnson by 105.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,366,660 shares of the company’s stock worth $342,266,000 after buying an additional 1,213,804 shares during the last quarter. Finally, American Money Management LLC grew its stake in Johnson & Johnson by 9.2% in the 4th quarter. American Money Management LLC now owns 37,404 shares of the company’s stock valued at $5,409,000 after buying an additional 3,148 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.3 %

JNJ opened at $163.63 on Friday. The firm has a market capitalization of $394.32 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company’s 50 day moving average price is $158.68 and its two-hundred day moving average price is $156.13. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Leerink Partners decreased their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.